Hester Biosciences Share Price Today | Stock Price & Hester Biosciences Share Screener
As of November 19, 2026, the live Hester Biosciences share price (NSE: HESTERBIO) is ₹2,352.10 on NSE and ₹2,346.10 on BSE, up 0.17% from the previous close, with shares trading between ₹2,329.00 and ₹2,424.00 in today's trading session, and a 52-week range of ₹1,259.10–₹2,545.00. Track HESTERBIO company valuation to gauge the company's total market size. Use the Hester Biosciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Hester Biosciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹102 and net income of ₹17, with EBITDA of ₹36, an operating margin of 34.0% and a profit margin of 16.7%.
Hester Biosciences Share Price Chart
Track the current stock price of Hester Biosciences with an interactive chart. Analyse HESTERBIO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Hester Biosciences stock quote in one place.
The quote of ₹2,352.10 sits between the 52-week low of ₹1,259.10 and the 52-week high of ₹2,545.00, and the latest session moved 0.17% from the previous close.
Hester Biosciences Company Profile - Fundamental Screener
Screen Hester Biosciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for HESTERBIO shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE782E01017.
Company Details
Classification
Identifiers and Leadership
Hester Biosciences Balance Sheet Screener
Screen HESTERBIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹678, up from ₹653 in 2025.
Latest statistics put total assets at ₹678 and shareholder funds at ₹368, with a leverage ratio of 0.60.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 678 | 653 | 662 | 670 | 562 | 411 | 387 | 300 | 244 | 213 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 412 | 233 | 240 | 259 | 237 | 133 | 142 | 145 | 110 | 103 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 158 | 202 | 254 | 233 | 198 | 114 | 97 | 70 | 44 | 48 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 368 | 327 | 303 | 289 | 267 | 236 | 207 | 181 | 145 | 127 |
| Share Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves & Surplus | 352 | 306 | 283 | 271 | 252 | 220 | 193 | 169 | 132 | 113 |
Hester Biosciences Income Statement Screener - Profit & Revenue Analysis
Screen Hester Biosciences income statement and profit fundamentals. Analyze HESTERBIO quarterly results. Hester Biosciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹102 and net profit was ₹17, equal to earnings per unit of ₹19.45, at an operating margin of 34%.
In that period expenses were ₹66, interest cost ₹5 and tax ₹9. The next period listed, 2026-Jun, shows revenue of ₹166 and net profit of ₹97.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 102 | 166 | 102 | 76 | 88 | 83 | 79 | 84 | 84 | 87 | 72 | 71 | 90 | 76 | 69 |
| Expenses | 66 | 55 | 65 | 63 | 61 | 59 | 60 | 63 | 65 | 65 | 58 | 56 | 74 | 57 | 57 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 36 | 112 | 37 | 14 | 26 | 24 | 20 | 21 | 20 | 22 | 14 | 15 | 17 | 19 | 12 |
| Operating Profit % | 34.00% | 29.00% | 33.00% | 23.00% | 27.00% | 17.00% | 23.00% | 20.00% | 21.00% | 23.00% | 8.00% | 17.00% | 16.00% | 19.00% | 15.00% |
| Depreciation | 6 | 7 | 7 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 4 | 4 |
| Interest | 5 | 3 | 3 | 6 | 2 | 2 | 2 | 7 | 5 | 6 | -4 | 1 | 3 | 8 | 2 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 25 | 102 | 27 | 4 | 20 | 17 | 14 | 10 | 11 | 12 | 13 | 8 | 9 | 7 | 6 |
| Tax | 9 | 5 | 6 | 2 | 3 | 3 | 4 | 4 | 3 | 4 | 2 | 3 | 2 | 3 | 2 |
| Net Profit | 17 | 97 | 21 | 2 | 17 | 14 | 9 | 6 | 8 | 8 | 11 | 6 | 7 | 4 | 4 |
| EPS | 19.45 | 113.71 | 23.94 | 1.82 | 20.33 | 16.85 | 10.94 | 7.52 | 8.80 | 9.86 | 13.41 | 6.72 | 7.89 | 4.75 | 4.73 |
Hester Biosciences Cash Flow Screener - Liquidity Fundamentals
Screen HESTERBIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹64, and net cash flow was an outflow of ₹3.
Over the same period, investing activities used ₹18 and financing activities used ₹49.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 64 | 65 | 48 | 24 | 9 | 58 | 37 | 47 | 38 | 35 |
| Investing Activities | -18 | -20 | -23 | -77 | -117 | -42 | -73 | -21 | -26 | -30 |
Financing and Net Cash | ||||||||||
| Financing Activities | -49 | -52 | -26 | 42 | 112 | -18 | 19 | 3 | -11 | 2 |
| Net Cash Flow | -3 | -7 | 0 | -12 | 4 | -2 | -17 | 28 | 1 | 6 |
Hester Biosciences Shareholding Pattern Screener
See Hester Biosciences shareholding pattern with promoter, FII, and DII holdings. Check Hester Biosciences promoter holding and ownership changes for HESTERBIO on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 53.73%, foreign institutions 0.38%, domestic institutions 0.00% and the public 33.29%, spread across 12,373 shareholders.
The shareholder count was 12,373 in 2026-Mar, compared with 11,961 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 53.73% | 53.73% | 44.28% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% |
Institutional Investors | ||||||||
| FII Holding | 0.38% | 0.31% | 0.31% | 0.87% | 0.52% | 0.53% | 0.51% | 0.43% |
| DII Holding | 0.00% | 0.00% | 0.08% | 0.02% | 0.02% | 0.00% | 0.01% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 33.29% | 33.00% | 32.70% | 32.64% | 32.80% | 32.92% | 33.06% | 33.32% |
| Other Holding | 12.60% | 12.95% | 22.63% | 12.73% | 12.93% | 12.82% | 12.68% | 12.52% |
| Shareholder Count | 12,373 | 11,961 | 11,685 | 11,853 | 11,810 | 12,260 | 12,603 | 12,844 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Hester Biosciences. Hester Biosciences dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹11.00 per unit for 2026-March, a yield of 0.47%, compared with ₹7.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹11.00, ₹7.00 and ₹6.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹11.00 | 0.47% |
| 2025-March | ₹7.00 | 0.56% |
| 2024-March | ₹6.00 | 0.48% |
| 2023-March | ₹8.00 | 0.57% |
| 2022-March | ₹10.00 | 0.64% |
| 2021-March | ₹10.00 | 0.37% |
| 2020-March | ₹6.60 | 0.34% |
| 2019-March | ₹11.00 | 1.20% |
| 2018-March | ₹10.00 | 0.65% |
| 2017-March | ₹5.30 | 0.33% |
Hester Biosciences Stock Index Membership - Nifty & Sensex
See which indices include Hester Biosciences stock. Check HESTERBIO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 3 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP.
Complete Index List
Hester Biosciences Market Events Screener - Corporate Actions
Get Hester Biosciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Hester Biosciences stock events that may affect HESTERBIO share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.
It is followed by Quarterly Result Announcement dated July 30, 2026 and Annual General Meeting dated July 21, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-05 | 2026-11-05 | Quarterly Result Announcement | NA | 12.50% |
| 2026-07-30 | 2026-07-30 | Quarterly Result Announcement | NA | 2.58% |
| 2026-07-21 | 2026-07-21 | Annual General Meeting | NA | 22.94% |
| 2026-07-14 | 2026-07-14 | Dividend | ₹ 11.00 /share | 45.84% |
| 2026-05-15 | 2026-05-15 | Quarterly Result Announcement | NA | 5.96% |
| 2026-01-30 | 2026-01-30 | Quarterly Result Announcement | NA | 1.41% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | 0.69% |
| 2025-08-13 | 2025-08-13 | Annual General Meeting | NA | 7.94% |
| 2025-08-06 | 2025-08-06 | Dividend | ₹ 7.00 /share | 19.29% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | 3.70% |
| 2025-05-09 | 2025-05-09 | Quarterly Result Announcement | NA | -4.77% |
| 2025-01-30 | 2025-01-30 | Quarterly Result Announcement | NA | -4.79% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -8.20% |
| 2024-08-29 | 2024-08-29 | Annual General Meeting | NA | -22.24% |
| 2024-08-22 | 2024-08-23 | Dividend | ₹ 6.00 /share | 52.21% |
Hester Biosciences Competitors Screener - Peer Stocks Comparison
Screen HESTERBIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 451,075 | 41.20 | 61,674 | 12.69% | 11,565 | 63.60 |
| Divis Laboratories | 303,749 | 90.40 | 11,067 | 13.95% | 2,568 | 78.53 |
| Torrent Pharmaceuticals | 177,632 | 85.50 | 13,886 | 20.34% | 2,138 | 47.27 |
| Laurus Labs | 130,972 | 97.10 | 6,868 | 22.01% | 890 | 69.60 |
| Zydus Life Science | 118,693 | 28.00 | 27,658 | 17.64% | 5,026 | 52.34 |
| Dr Reddys Laboratories | 115,186 | 42.00 | 35,059 | 3.90% | 4,158 | 70.24 |
| Cipla | 112,438 | 39.90 | 29,045 | 2.24% | 3,870 | 54.92 |
| Mankind Pharma | 109,044 | 48.10 | 14,636 | 14.85% | 1,938 | 65.43 |
| Aurobindo Pharma | 104,903 | 26.00 | 34,145 | 5.56% | 3,503 | 66.06 |
| Lupin | 90,557 | 17.60 | 29,039 | 26.75% | 5,356 | 44.92 |
Hester Biosciences Company Announcements - News & Reports Screener
Screen HESTERBIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 12, 2026.
The next most recent announcements are dated November 11, 2026 and November 10, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-11-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-11-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-11-10 | Announcement Under Regulation 30 Of Listing Regulations - Approved An Unsecured Loan To Foreign Wholly-Owned Subsidiary | - |
| 2026-11-10 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-11-10 | Board Meeting Outcome for Outcome Of Board Meeting And Financial Results | - |
| 2026-10-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-27 | Board Meeting Intimation for Financial Results | - |
| 2026-10-27 | Announcement Under Regulations 30 (LODR) - Completion Of Tenure Of Independent Director | - |
| 2026-10-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-06 | Disclosure Under Regulation 30 Of The SEBI Listing Regulations For Investment In Limited Liability Partnership For Group Captive Power Generation | - |
| 2026-10-06 | Board Meeting Outcome for Outcome Of Board Meeting Held Today | - |
| 2026-09-25 | Closure of Trading Window | - |
| 2026-09-04 | Shareholders Approval For Reclassification From Promoter And Promoter Group Category To Public Category Shareholders | - |
| 2026-09-04 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-09-04 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-08-27 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-08-04 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-08-01 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-07-31 | Launch Of Interactive Microsite Of 39Th Annual Report FY 2025-26 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹2,352.10, within a 52-week range of ₹1,259.10 to ₹2,545.00. The P/E ratio is 13.90 and the P/B ratio is 4.24, with earnings per unit of ₹67.57. Market capitalisation stands at ₹1,976.66 Cr and the dividend yield is 0.47%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.